Drug intelligence / Profile preview

Q-REstrain

Development stage: Preclinical
Lead developer: Research Genetic Cancer Centre Group
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

Q-REstrain is an autologous, non-manipulated microRNA-based RNA interference (RNAi) therapy developed by the Research Genetic Cancer Centre Group (RGCC). It is designed to regulate gene expression by modulating messenger RNA (mRNA) activity. The therapy is intended for use in cancer, viral conditions, and respiratory conditions. RGCC describes Q-REstrain as a supportive approach and autologous innovation that utilizes the patient's own biological components to interfere with specific genetic pathways associated with disease progression. It is part of a broader suite of personalized therapeutic innovations offered through the RGCC network.

Brand names: Q-REstrain

Beyond the preview

Go deeper on Q-REstrain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-REstrain.

Explore the full profile